Tuberculosis. 3 As a critical first step in moving forward, the Roadmap highlighted the need Increased use of modelling and better data on which to build models will improve the 296 accuracy of new estimates. It is also possible to use modelling to identify which data inputs 297 contribute most to the uncertainty in the overall estimates. Such analysis can consequently 298 hep prioritize areas of primary data collection for improving the accuracy of estimates.
299
Comparison and synthesis of modelling methodology will also help. Assessing these 300 estimates over time also allows an appreciation of changing trends. Ideally, further 301 disaggregation of reported data would take place so that children are reported in five-year There has been increased investment and significant progresses in scientific research. 325 However, we are still some way from a complete understanding of which children get TB 326 and how best to find them. NIH. The funder had no role in the decision to publish this manuscript. These expected values provide a rule-of-thumb or guide only. Enormous variability in these parameters has been described in studies across different settings 2 Since 2013, cases are now reported to WHO according to whether bacteriologically confirmed, which includes confirmation by smear microscopy, culture and Xpert MTB/RIF Accurate data of the burden of tuberculosis in children are required to engage the leadership and support of the tuberculosis control sector, the child health sector, government health ministries, advocacy groups and the wider community.
Inform situational analysis and identify gaps I priorities for implementation to address child tuberculosis.
Child TB is an indicator for surveillance of recent transmission
Accurate data of tuberculosis in young children monitored over time could be an important tuberculosis control indicator as a sensitive indicator of recent transmission and an early indicator of -Resource allocation for health systems and NTP The numbers of children with drug-sensitive and drug-resistant tuberculosis will inform health service and human resource requirements to ensure effective programmatic management.
Procurement needs of diagnostics and therapeutics
The numbers of children with drug-sensitive and drug-resistant tuberculosis will inform the needs and sufficient procurement of diagnostic tools and anti-tuberculosis medication, including medication suitable for young children.
Engage the Maternal and Child Health sector
Data that show the importance of tuberculosis in the context of child morbidity and mortality are required to engage the leadership and support of the Maternal and Child Health sector and government, especially as most countries include child health as a major national priority.
Advocacy and engagement of civil society
Accurate data of the burden of tuberculosis with direct and indirect consequences on child health are extremely valuable for advocacy groups, national champions and civil society to highlight the need for action.
Monitoring and evaluation tool Accurate baseline data are required to monitor and evaluate implementation of activities aiming to improve the detection, prevention and management of child tuberculosis. Identification of needs and improves quality of research Accurate data would greatly strengthen the many opportunities for operational research in children as well as the quality of clinical trials that evaluate novel diagnostics or therapeutic regimens. Potential for investment in novel diagnostics and therapeutics 
